Related Articles
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition
Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP‑Ribose) polymerase inhibitors against BRCA1/2 wild‑type ovarian cancer
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin
MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells